RESUMO
Apex and Gophee are mycobacteriophages directly isolated from soil using the host Mycobacterium smegmatis mc2155. Apex has a 71,244-bp double-stranded DNA (dsDNA) genome encoding 98 putative proteins, and Gophee has a 68,556-bp dsDNA genome encoding 101 putative proteins.
RESUMO
Mycobacteriophages Joselito, Patt, and Tydolla were isolated from different soil or water samples using Mycobacterium smegmatis mc2155 as the host. Each was obtained using direct isolation techniques, purified, and then sequenced using the deconvolution of genomes after en masse sequencing (DOGEMS) method.
RESUMO
EleanorGeorge, Mattes, and Spikelee are mycobacteriophages isolated from different soil samples using Mycobacterium smegmatis mc2155 as the host. Each was obtained using direct isolation techniques, purified, and then sequenced. Based on sequence similarity, all three belong to the F1 subcluster and are temperate phages.
RESUMO
Since 1989, we have been involved in the development of a vaccine against Haemophilus influenzae type b. The new vaccine is based on the conjugation of synthetic oligosaccharides to tetanus toxoid. Our main goals have been (i) to verify the feasibility of using the synthetic antigen and (ii) to search for new production alternatives for this important infant vaccine. Overall, eight trials have already been conducted with adults, children (4 to 5 years old), and infants. We have described herein the details from the first two phase I clinical trials conducted with human adult volunteers under double blind, randomized conditions. The participants each received a single intramuscular injection to evaluate safety and initial immunogenicity. We have found an excellent safety profile and an antibody response similar to the one observed for the control vaccine.
Assuntos
Infecções por Haemophilus/prevenção & controle , Vacinas Anti-Haemophilus/administração & dosagem , Haemophilus influenzae tipo b/imunologia , Adulto , Anticorpos Antibacterianos/sangue , Especificidade de Anticorpos , Método Duplo-Cego , Ensaio de Imunoadsorção Enzimática , Infecções por Haemophilus/imunologia , Vacinas Anti-Haemophilus/efeitos adversos , Vacinas Anti-Haemophilus/imunologia , Humanos , Imunoglobulina A/imunologia , Imunoglobulina G/imunologia , Imunoglobulina M/imunologia , Masculino , Estudos Retrospectivos , Teste Bactericida do Soro , Vacinas ConjugadasRESUMO
Since 1989, we have been involved in the development of a vaccine against Haemophilus influenzae type b. The new vaccine is based on the conjugation of synthetic oligosaccharides to tetanus toxoid. Our main goals have been (i) to verify the feasibility of using the synthetic antigen and (ii) to search for new production alternatives for this important infant vaccine. Overall, eight trials have already been conducted with adults, children (4 to 5 years old), and infants. We have described herein the details from the first two phase I clinical trials conducted with human adult volunteers under double blind, randomized conditions. The participants each received a single intramuscular injection to evaluate safety and initial immunogenicity. We have found an excellent safety profile and an antibody response similar to the one observed for the control vaccine(AU)
Desde 1989, hemos participado en el desarrollo de una vacuna contra el Haemophilus influenzae tipo b. La nueva vacuna se basa en la conjugación de oligosacáridos sintéticos a toxoide tetánico. Nuestros principales objetivos han sido (i) para verificar la viabilidad de la utilización de la síntesis de antígenos y (ii) búsqueda de nuevas alternativas de producción para este importante vacuna infantil. En total, ocho ensayos ya se han realizado con adultos, niños (de 4 a 5 años), y los lactantes. Hemos descrito en este documento los detalles de los dos primeros ensayos clínicos de fase I realizado con voluntarios adultos humanos en virtud de doble ciego, randomizado condiciones. Los participantes recibieron una única inyección intramuscular para evaluar la seguridad y la inmunogenicidad inicial. Hemos encontrado un excelente perfil de seguridad y una respuesta de anticuerpos similar a la observada para el control de vacunas
